Co-irbesan tablets are shown for treatment of essential hypertensia.

This combination with the fixed dose is shown by

to adult patients whose arterial blood pressure cannot only be controlled properly irbesartany or a hydrochlorothiazide.

Structure

Active ingredient: irbesartan; hydrochlorothiazide;

1 tablet, coated, supports an irbesartan of 150 mg and a hydrochlorothiazide of 12.5 mg of an irbesartan of 300 mg and a hydrochlorothiazide of 12.5 mg;

Excipients: lactose, cellulose microcrystalline, sodium of a kroskarmelloz, silicon dioxide colloidal, magnesium stearate, a covering * Opadry Pink OY - 34948;

* Structure of a covering of Opadry Pink OY - 34948: hydroksipropilmetiltsellyuloza (2910), polyethyleneglycol 400, titan dioxide (E 171), ferrous oxide red (E 172).

Contraindication

• Hypersensitivity to active agents or to any of excipients, or to any of substances which are derivatives of sulfonamides (a hydrochlorothiazide - the substance derivative of sulfonamides).
• Severe form of a renal failure (clearance of creatinine <30 ml/min.).
• Steady form of a hypopotassemia, hypercalcemia.
• Severe form of a liver failure, cirrhosis and cholestasia.
• Simultaneous use of the medicament Co-Irbesan® with the medicaments containing aliskerin, to patients, sick diabetes and to patients with moderate and severe damage of kidneys (glomerular filtration rate <60 ml/min. / 1.73 sq.m).
• Simultaneous use of the medicament Co-Irbesan® with inhibitors the angiotensin of the turning enzyme (ATE) at patients with a diabetic nephropathy.
• hypopotassemia, Resistant to treatment, or hypercalcemia.
• Refractory hyponatremia.
• Symptomatic hyperuricemia (gout).
• Anury.
• Period of pregnancy and feeding by a breast.
• Children's age.

Route of administration

Co-Irbesan® is applied 1 time a day irrespective of meal.

Can recommend to

titration of a dose separate components (i.e. irbesartany and a hydrochlorothiazide).

At clinical expediency can consider the possibility of direct transition from monotherapy to fixed combinations:

/ 12.5 mg patients whose arterial blood pressure cannot be controlled properly one hydrochlorothiazide can apply

Ко-Ирбесан® 150 mg or irbesartany in a dose of 150 mg

/ 12.5 mg patients whose arterial blood pressure is insufficiently controlled irbesartany mg in a dose of 300 mg of medicament Ко-Ирбесан® 150 / 12.5 by mg can apply

Ко-Ирбесан® 300 mg.

more than 300 mg irbesartana/25 mg of a hydrochlorothiazide of 1 times a day are not recommended to

Dose.

In need of Co-Irbesan® can be applied with other antihypertensive medicines.

to

Feature of use

to

Pregnant

to

It is contraindicated.

to

Children

to

It is contraindicated.

Drivers

With care.

Overdose

Is not present special information on overdose treatment by the medicament Co-Irbesan®.

Patient has to undergo careful monitoring, and treatment has to be symptomatic and supporting. Treatment depends on time which passed from the moment of use of means, and weight of symptoms. The actions provided include: to cause vomiting and or to wash out a stomach. At treatment of overdose it is possible to apply activated carbon. It is necessary to control often the level of electrolytes and creatinine in blood serum. When developing arterial hypotension of the patient it is necessary to put in horizontal position and to quickly apply saline solutions and to carry out completions of volume of liquid.

Side effects

• from nervous system: dizziness.
• from digestive tract: nausea/vomiting.
• from kidneys and an urinary system: urination disturbance.
• from vessels: orthostatic hypotension.
• General disorders: increased fatigue.
• from skin and hypodermic cellulose: itching.

Interaction

Alcohol. Can lead to orthostatic hypotension.

Methyldopum. It was reported about separate cases of developing of hemolytic anemia at simultaneous use of a hydrochlorothiazide and Methyldopums.

Salicylates. At use of high doses of salicylates of a hydrochlorothiazide can strengthen their toxic impact on the central nervous system.

Cyclosporine. At simultaneous use of cyclosporine the hyperuricemia can amplify and increase risk of complications as gout.

Storage conditions

to Store

at a temperature not above 25 °C in original packing.

to Store

out of children's reach.

Expiration date - 3 years.